Perspectives Concerning SARS-CoV-2 Transmission for the Application of the Livestock Breeding

Updata:01-01-1970

Source:
By:Author(s)

DOI: https://doi.org/10.30564/jzr.v4i1.4264

Abstract:

Viral transmission between animals and humans has been defined as Zoonosis and zooanthroponosis. The vaccine has been claimed to be the best tool to prevent viral epidemics. However, as learned from SARSCoV-2, vaccines cannot be the true answer to prevent viral infection for everyone. Some vaccinated persons are still reported to get infected. Viral mutation has been principally postulated to explain immune evasion. Questionable, why the mutated viral strain does not evade the immunity of everyone who has been vaccinated? Mutated viral strains cause various symptoms, nonsymptomatic to morbidity and mortality, in different individuals with more or less the same ratio as the original SARS-CoV-2. Approximately, 25-35% of the SARSCoV-2 detected individuals are asymptomatic, while 15- 20% developed severity and about 2-5% have critical symptoms [1,2]. Logically, the viral mutation could keep mutating in any part of its genome. The new variant might maintain infectivity in the same person and might develop to infect another person who once has not been susceptible to the original strain. Thus, the dynamics of viral infection could change from time to time. This requires a better explanation to lead us in the right direction to prevent the emergent virus either now or in the future.

References:

[1]Oran, D.P., Topol, E.J., 2021. The proportion of SARS-CoV-2 infections that are asymptomatic: A systematic review. Ann Intern Med. 174(5), 655-62. [2]Sakurai, A., Sasaki, T., Kato, S., et al., 2020. Natural History of Asymptomatic SARS-CoV-2 Infection. N Engl J Med. 383(9), 885-6. [3]Asselta, R., Paraboschi, E.M., Mantovani, A., Duga, S., 2020. ACE-2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY). 12(11), 10087-98. [4]Latini, A., Agolini, E., Novelli, A., et al., 2020. COVID-19 and genetic variants of protein involved in the SARS-CoV-2 entry into the host cells. Genes (Basel). 11(9), 1010. [5]Vardhan, S., Sahoo, S.K., 2021. Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells. J Tradit Complement Med. Advance online publication. [6]Lu, X., Gibbs, J.S., Hickman, H.D., et al., 2012. Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters. Proc Natl Acad Sci USA. 109(38), 15407-12. [7]Romagnoli, P.A., Premenko-Lanier, M.F., Loria, G.D., Altman, J.D., 2013. CD8 T cell memory recall is enhanced by novel direct interactions with CD4 T cells enabled by MHC class II transferred from APCs. PLoS One. 8(2), e56999. DOI: https://doi.org/10.1371/journal.pone.0056999. Epub 2013 Feb 18. PMID: 23441229; PMCID: PMC3575485. [8]Engels, N., Wienands, J., 2018 May. Memory control by the B cell antigen receptor. Immunol Rev. 283(1), 150-160. DOI: https://doi.org/10.1111/imr.12651. PMID: 29664567. [9]Shimoda, M., Koni, P.A., 2007. MHC-restricted B-cell antigen presentation in memory B-cell maintenance and differentiation. Crit Rev Immunol. 27(1), 47-60. DOI: https://doi.org/10.1615/critrevimmunol.v27. i1.40. PMID: 17430096. [10]Sun, X., Wang, T., Cai, D., et al., 2020. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 53, 38-42. [11] Fara, A., Mitrev, Z., Rosalia, R.A., Assas, B.M., 2020. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 10(9), 200160.

Tags: